Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages 1547-1555

  Jabbour, Elias ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a   Thomas, Deborah ^a   Huang, Xuelin ^a   Faderl, Stefan ^a   Pemmaraju, Naveen ^a   Daver, Naval ^a   Garcia Manero, Guillermo ^a   Sasaki, Koji ^a   Cortes, Jorge ^a   Garris, Rebecca ^a   Yin, C Cameron ^a   Khoury, Joseph D ^a   Jorgensen, Jeffrey ^a   Estrov, Zeev ^a   Bohannan, Zachary ^a   Konopleva, Marina ^a   Kadia, Tapan ^a   Jain, Nitin ^a   DiNardo, Courtney ^a   Wierda, William ^a   Jeanis, Vicky ^a   O'Brien, Susan ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MESNA; METHOTREXATE; NILOTINIB; PONATINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRIACYLGLYCEROL LIPASE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; BLEEDING; BULLOUS SKIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARDIOVASCULAR EFFECT; CAUSE OF DEATH; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY INJURY; KIDNEY VEIN THROMBOSIS; LUNG EMBOLISM; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; NAUSEA; PANCREATITIS; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VASCULAR DISEASE; VISUAL DISORDER; VOMITING; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIDAZINES; VINCRISTINE;

EID: 84961063499     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00207-7     Document Type: Article

References (34)

1. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014, 123:843-850.
2. Ravandi F, O'Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010, 116:2070-2077.
3. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27:5175-5181.
4. Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVA and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). Proc Am Soc Clin Oncol 2010, 28(suppl):15. abstr 6506.
5. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant 2013, 19:150-155.
6. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010, 28:3644-3652.
7. Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2010, 116. abstract 173.
8. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469-1477.
9. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357-2366.
10. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
11. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
13. Rousselot P, Coude MM, Huguet F, et al. Dasatinib and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 study. Blood 2012, 120(suppl 1). abstr 666.
14. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, 118:6521-6528.
15. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
16. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
17. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
18. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels 1994, 253-256. Criteria Committee of the New York Heart Association, Boston, MA, Little, Brown & Co. 9th edn.
19. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396-4407.
20. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788-2801.
21. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010, 28:3880-3889.
22. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013, 122:1214-1221.
23. Luthra R, Sanchez-Vega B, Medeiros LJ TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol 2004, 17:96-103.
24. Branford S, Fletcher L, Cross NS, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008, 112:3330-3408.
25. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008, 113:985-994.
26. Weir EG, Cowan K, LeBeau P, Borowitz MJ A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999, 13:558-567.
27. Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014, 120:1002-1009.
28. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015, 125:3711-3719.
29. Cortes JE, Ibarz JP, Coutre PL, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014, 124(suppl). abstract 3135.
30. Valent P, Hadzijusufovic E, Schernthaner G, Wolf D, Rea D, le Coutre P Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015, 125:901-906.
31. Rivera VMPJ, Gonzalvez F, Baker F, Gozgit JM, Hodgson G Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events. Blood 2014, 124(suppl). abstract 1783.
32. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood 2013, 122(suppl). abstract 257.
33. Knickerbocker R, Haluska FG, Baccarani M, Cortes J, Hochhaus A, Talpaz M Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Blood 2014, 124(suppl). abstract 4546.
34. Fielding AK Philadelphia-positive acute lymphoblastic leukemia-is bone marrow transplant still necessary?. Biol Blood Marrow Transplant 2011, 17:S84-S88.